Bone mineral density increase

Bone mineral density increase refers to the rise in the amount of mineral content per unit area in bones. It is not a molecule or receptor but rather a clinical endpoint and quantitative measure used in the diagnosis and management of osteoporosis and other metabolic bone diseases. Increases in bone mineral density are typically achieved through modulation of cellular pathways involving osteoblasts and osteoclasts—such as those regulated by RANK/RANKL/OPG signaling, Wnt/LRP5 pathway, parathyroid hormone activity, estrogen effects on bone cells, among others[1][2][3]. Drugs like bisphosphonates, denosumab (RANKL inhibitor), teriparatide/parathyroid hormone analogues, selective estrogen receptor modulators, and sclerostin inhibitors act on these underlying molecular targets to ultimately produce an increase in BMD. Therefore "bone mineral density increase" should be considered an outcome or biomarker rather than a canonical drug target. In summary: "Bone mineral density increase" is not itself a molecule/receptor/therapeutic target but rather an endpoint reflecting changes mediated by multiple underlying biological targets.

Other names

Bone density increaseIncreased bone mineral densityBMD increase